Ocuphire Pharma, Inc. (NASDAQ:OCUP) Stock Holdings Lifted by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC raised its stake in Ocuphire Pharma, Inc. (NASDAQ:OCUP) by 323.4% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 42,341 shares of the company’s stock after acquiring an additional 32,341 shares during the period. Kestra Private Wealth Services LLC’s holdings in Ocuphire Pharma were worth $127,000 at the end of the most recent reporting period.

Separately, Acadian Asset Management LLC raised its stake in Ocuphire Pharma by 75.5% during the 3rd quarter. Acadian Asset Management LLC now owns 49,563 shares of the company’s stock valued at $165,000 after purchasing an additional 21,318 shares during the period. Institutional investors and hedge funds own 14.97% of the company’s stock.

Insider Transactions at Ocuphire Pharma

In related news, CEO George Magrath purchased 25,000 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were acquired at an average cost of $1.96 per share, with a total value of $49,000.00. Following the completion of the purchase, the chief executive officer now owns 425,000 shares of the company’s stock, valued at approximately $833,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have purchased 37,000 shares of company stock valued at $74,100. 8.70% of the stock is owned by insiders.

Ocuphire Pharma Stock Up 7.1 %

Shares of NASDAQ:OCUP opened at $1.96 on Friday. The company’s fifty day moving average is $1.94 and its two-hundred day moving average is $2.50. Ocuphire Pharma, Inc. has a 12-month low of $1.50 and a 12-month high of $6.60. The company has a market cap of $50.20 million, a P/E ratio of -4.08 and a beta of 0.39.

Ocuphire Pharma (NASDAQ:OCUP) last announced its earnings results on Friday, March 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.14). Ocuphire Pharma had a negative net margin of 52.42% and a negative return on equity of 22.30%. The firm had revenue of $1.69 million for the quarter, compared to analyst estimates of $3.47 million. Equities research analysts anticipate that Ocuphire Pharma, Inc. will post -0.53 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Alliance Global Partners cut their target price on shares of Ocuphire Pharma from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, March 20th.

About Ocuphire Pharma

Ocuphire Pharma, Inc, a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances.